Policy & Regulations

Pfizer scans India for shopping options

October 22nd, 2009|

Pfizer has approached several Indian drugmakers for possible alliances as part of moves to try and bolster revenues threatened by the expiry of patents on key blockbuster drugs in the next three years, three persons with direct knowledge of the matter said.

Sanofi-aventis sees new opportunities in Quebec

October 22nd, 2009|

A North American reorganization at pharmaceutical company Sanofi-aventis could provide its manufacturing operations in Laval with new opportunities.

Glenmark Pharma plans to list its generics subsidiary

October 13th, 2009|

Glenmark Pharmaceuticals is planning to list its generics subsidiary — Glenmark Generics — and has filed a draft red herring prospectus with SEBI.

Pfizer completes Wyeth merger

October 13th, 2009|

Pfizer expects to complete its $68 billion acquisition of Wyeth today after receiving sign-off on the deal from regulators in the US and Canada.


October 13th, 2009|

Small and medium pharmaceutical companies are in a state of crisis. Their new set of problems started with the implementation of Good Manufacturing Practices as per the amended norms of Schedule M of the Drugs & Cosmetics Act in 2005.

Big Pharma targets emerging mkts

October 11th, 2009|

GlaxoSmithKline (GSK) announced a joint venture in China for the manufacture and distribution of vaccines in the region. This was the second such alliance for GSK this year in that country. In June, the company had signed an agreement with a Chinese biotech company to develop and manufacture flu vaccines.

Glaxo eyes Dr Reddys as Big Pharma hunts in India

October 7th, 2009|

Western drugmakers are stepping up the hunt for emerging market "tigers" in India.

Pharma enters emerging markets via generics

October 7th, 2009|

Major pharmaceutical companies see generics as a bridge to the futureMOST PHARMACEUTICAL innovators treat patent expiry like a terminal disease and the generics business as a sort of hospice where dying products ease into commodity oblivion, but recent deals and acquisitions suggest growing faith in an afterlife of emerging markets.

Indian formulation mkt to cross US dollars 13.7 billion by 2013

October 4th, 2009|

The surging demand in the domestic market coupled with an increased focus from the multinational pharma companies for contract research and manufacturing services (CRAMS) are set to fuel the Indian pharmaceutical growth in the years to come.

IPA(MP) to organize seminar on enforcement and implications of Spurious Drugs Act

September 29th, 2009|

The Indian Pharmaceutical Association, Madhya Pradesh State Branch, Indore (IPA, MPSB) is organizing a one-day seminar on 'Drugs and Cosmetics (Amendment) Act, 2008: Enforcement, implications and provisions' on October 3 at Hotel Sayaji in Indore.

Wockhardt gets US nod for Tamsulosin capsules

September 29th, 2009|

Pharma major Wockhardt Tuesday got the US Food and Drug Administration's (USFDA) tentative approval for marketing Tamsulosin Hydrochloride capsules.

Pharma M and As sounding death knell for low-cost drugs?

September 29th, 2009|

It began in 2006, with the Hyderabad based Matrix Labs becoming a subsidiary of a US company. Then it was Ranbaxy Labs' turn to get sold to a Japanese major. Vaccine player Shantha Biotech followed suit in July this year by being bought over by a French company.

Sanofi-Aventis scans India for acquisitions

September 28th, 2009|

Sanofi-Aventis, the $42-billion French drug maker, which bought companies in Brazil, Mexico, and the home-grown Shanta Biotech this year, has sent a delegation to India to finalise another target for acquisition in a market that is estimated to be worth more than $17 billion and growing, two persons familiar with the matter said.

Wockhardt is top Indian pharma patentee bags government award

September 28th, 2009|

Pharmaceutical and biotechnology major Wockhardt Limited has received the Government of India award for the maximum number of patents filed and granted in India by any pharmaceutical company.

Growing pharma market makes India a clinical trial destination: Report

September 28th, 2009|

The domestic pharmaceutical market is expected to triple to $20 billion by 2015 from the current $7 billion and move into the world’s top 10 markets.

Mega deals boost pharma in crisis

September 14th, 2009|

Following the collapse of Lehman Brothers and the global meltdown, pharmaceuticals is perhaps the only sector globally which withstood it all, announcing a slew of deals month after month.

Mid-cap pharma firms focus on LatAm market

September 10th, 2009|

Lupin and Glenmark Pharmaceuticals are leading Indian mid-cap drug makers in exploiting rising demand for medicines in South American nations, such as Brazil and Argentina, even as competition and rules intensify in the developed markets of the US and Europe.

Pfizer plans major push into generics

September 10th, 2009|

Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market.

AVESTHAGEN to raise Rs. 700 crore from domestic and international markets

September 7th, 2009|

Bangalore-based life sciences company AVESTHAGEN has revived plans for an IPO and the company will raise approximately Rs 600-700 crores from the domestic and international markets.

North Indian Pharma: Focusing on R and D and Tie-ups to Meet Challenging conditions

August 24th, 2009|

The North India based listed pharmaceutical companies have established strong presence in the domestic market, highly regulated markets and emerging markets during the last couple of years with several US FDA approved facilities, high-tech R&D laboratories, focus on new lifestyle drugs and partnership with international giants.